Dyslipidemia in Obesity: Mechanisms and Potential Targets
Open accessThe DOI matches its Crossref record; 166 of the 169 references it cites were found in a registry or an index; 5 of the 56 sources its claims cite were checked for support.
Abstract
Obesity has become a major worldwide health problem. In every single country in the world, the incidence of obesity is rising continuously and therefore, the associated morbidity, mortality and both medical and economical costs are expected to increase as well. The majority of these complications are related to co-morbid conditions that include coronary artery disease, hypertension, type 2 diabetes mellitus, respiratory disorders and dyslipidemia. Obesity increases cardiovascular risk through risk factors such as increased fasting plasma triglycerides, high LDL cholesterol, low HDL cholesterol, elevated blood glucose and insulin levels and high blood pressure. Novel lipid dependent, metabolic risk factors associated to obesity are the presence of the small dense LDL phenotype, postprandial hyperlipidemia with accumulation of atherogenic remnants and hepatic overproduction of apoB containing lipoproteins. All these lipid abnormalities are typical features of the metabolic syndrome and may be associated to a pro-inflammatory gradient which in part may originate in the adipose tissue itself and directly affect the endothelium. An important link between obesity, the metabolic syndrome and dyslipidemia, seems to be the development of insulin resistance in peripheral tissues leading to an enhanced hepatic flux of fatty acids from dietary sources, intravascular lipolysis and from adipose tissue resistant to the antilipolytic effects of insulin. The current review will focus on these aspects of lipid metabolism in obesity and potential interventions to treat the obesity related dyslipidemia.
Overview
CoChat Summary
TL;DR
This narrative review describes how obesity-related insulin resistance, impaired triglyceride lipolysis, increased free fatty acid flux, and altered apolipoprotein/complement metabolism produce the characteristic dyslipidemia of high triglycerides, small dense LDL, and low HDL-C. It summarizes lifestyle and pharmacological approaches, emphasizing weight loss, statins, fibrates, niacin, omega-3 fatty acids, and apoB/non-HDL-C as treatment targets.
Key findings
- The hallmark of obesity dyslipidemia is elevated fasting and postprandial TG, small dense LDL, low HDL-C, and normal or slightly increased LDL-C, with increased apoB; hypertriglyceridemia may be the major cause of the other lipid abnormalities.
- Mechanisms include insulin resistance with enhanced hepatic FFA flux, hepatic overproduction of apoB-containing lipoproteins, reduced LPL mRNA in adipose tissue and LPL activity in skeletal muscle, elevated apo C-III, increased CETP-mediated lipid exchange, hepatic lipase action, and reduced LDL receptor expression; ASP mRNA expression in visceral adipose tissue is reduced by approximately 40% in obese and morbidly obese subjects versus lean controls.
- Atherogenic features include small dense LDL with a five-day residence time and chylomicron remnants that contain approximately 40 times more cholesterol per particle than LDL; postprandial hyperlipidemia with atherogenic remnants is especially linked to visceral obesity.
- Treatment findings include: weight loss of 4–10 kg reduced LDL-C by 12% and increased LDL receptor mRNA by 27%; moderate weight loss of approximately 10% reduced postprandial TG by 27%–46%; fibrates reduce TG by approximately 30%, LDL-C by 8%, and increase HDL-C by an average of 9%; niacin lowers TG by 15%–35% and raises HDL-C by 10%–25%; omega-3 fatty acids reduce plasma TG by 25%–30%; ezetimibe gives an additional 20% LDL-C lowering.
Methods
- Narrative review of lipid metabolism in obesity, including general lipoprotein metabolism, obesity-induced changes, FFA/inflammation interplay, lifestyle interventions, and pharmacological treatment.
- No primary data or study sample; the paper synthesizes published literature and cites prior studies, including metabolic ward studies, stable isotope studies, randomized trials, and meta-analyses.
- Main analysis is qualitative synthesis; no systematic search strategy, meta-analysis, or formal quality assessment is described.
Limitations
- The paper does not explicitly state limitations of the review itself. It notes evidence gaps, including that specific data on niacin plus statins in obesity remain scarce, that increasing HDL-C by exercise remains controversial, and that controversy exists about fibrate therapy on top of statin therapy.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal risk-of-bias assessment, and it reports no primary outcomes of its own.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
4 Valid · 0 Not valid · 28 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Visceral obesity leads to insulin resistance in part mediated by adipokines and free fatty acids (FFA).”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 1. Introduction
What the sources say
- Supportedcites [2] Flock, 2011, Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol, Adv. Nutr. source
The “Potential mechanisms altering lipid metabolism” section says excess adipose tissue leads to insulin resistance and identifies circulating adipokines and fatty acids as contributors. The “Weight reduction improves insulin sensitivity and LDL uptake” section specifically links abdominal adiposity with insulin resistance. Page numbers are not available in our copy. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The amount of liberated FFA from chylomicrons and VLDL depends on the activity of LPL, which is stimulated by insulin [17,18].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 2. Overview of Lipoprotein Metabolism
What the sources say
- Partly supportedcites [17] Karpe, 2011, Fatty acids, obesity, and insulin resistance: Time for a reevaluation, Diabetes sourceExperimental — accuracy not yet measured
Karpe et al. (2011) support the first half of the sentence: in FATTY ACIDS AND METABOLIC PHYSIOLOGY they state that 'Lipoprotein lipase (LPL) in the capillaries of adipose tissue hydrolyses circulating TG, mainly the dietary fat carried in the chylomicrons,' that VLDL-TG is likewise hydrolysed by LPL, and that 'the lower LPL activity leaves more TG unlipolysed in the triglyceride-rich lipoproteins' — i.e. the amount of fatty acid liberated depends on LPL activity. However, no passage of our copy (searched: LPL stimulated by insulin, insulin action on adipose LPL/activity, LPL activity determining fatty acid release) states that LPL activity is stimulated by insulin; the only acute LPL activation described is by heparin ('Heparin releases LPL from its endothelial binding sites and also activates the enzyme,' PATHOPHYSIOLOGY), and insulin's role in the paper is antilipolytic suppression of fat mobilization (METABOLIC PHYSIOLOGY). The insulin-stimulation clause attributed to this source is therefore not supported. (LLM, conf=0.75)
- Supportedcites [18] McQuaid, 2011, Downregulation of adipose tissue fatty acid trafficking in obesity: A driver for ectopic fat deposition?, Diabetes source
The Abstract (CONCLUSIONS) of our copy states in its own voice that 'In the postprandial period, insulin stimulates fat deposition into adipose tissue. This occurs by hydrolysis of chylomicron triglycerides (TGs) by lipoprotein lipase (LPL) bound to capillary endothelium', i.e. insulin drives the LPL-mediated liberation of fatty acids from TG-rich lipoproteins. The Discussion adds that LPL mediates lipolysis of both chylomicron and VLDL-TG and that postprandial upregulation of adipose tissue LPL occurs in lean but not obese subjects, consistent with insulin stimulation of LPL activity. This is background framing in the cited paper rather than its own experimental measurement, but our copy clearly treats the topic as stated. (LLM, conf=0.80)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, it has been described that ASP mRNA expression in visceral adipose tissue is reduced by approximately 40% in obese and morbidly obese subjects with or without insulin resistance when compared to lean controls [50].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 4. Interplay between FFA Metabolism and Inflammation in Obesity: Crossroad between Innate Immunity and Lipid Metabolism
What the sources say
- Partly supportedcites [50] Tinahones, 2011, Adipose tissue gene expression of factors related to lipid processing in obesity, PLoS One sourceExperimental — accuracy not yet measured
The Results state that visceral adipose tissue C3/ASP mRNA expression was higher in lean controls than in every obese group. But Table 2 shows reductions of about 44% in obese subjects and 49% in morbidly obese subjects with low insulin resistance, versus about 23% in the morbidly obese high-insulin-resistance/T2DM group. Thus, the approximately 40% reduction does not describe all the groups claimed. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“It is widely recognized that plasma FFA are elevated in obese people as a consequence of an increased fatty acid release from adipose tissue and a reduction in plasma FFA clearance [85,86,87].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 4. Interplay between FFA Metabolism and Inflammation in Obesity: Crossroad between Innate Immunity and Lipid Metabolism
What the sources say
- Not checked yetcites [85] Bjorntorp, 1969, Plasma free fatty acid turnover rate in obesity, Acta Med. Scand. source
- Not checked yetcites [86] Mook, 2004, In vivo regulation of plasma free fatty acids in insulin resistance, Metabolism source
- Not checked yetcites [87] Verseyden, 2004, Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 3, Am. J. Clin. Nutr. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The exchange of TG from these remnants for cholesterol-esters from HDL by CETP with the concerted action of hepatic lipase, ultimately leads to the formation of small dense LDL [48,49].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 3. Obesity Induced Changes in Lipoprotein Metabolism and Atherogenic Effects
What the sources say
- Not checked yetcites [48] Capell, 1996, Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B, Arterioscler Thromb. Vasc. Biol. source
- Not checked yetcites [49] Hokanson, 1995, LDL physical and chemical properties in familial combined hyperlipidemia, Arterioscler. Thromb. Vasc. Biol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
14 more claims
Create a free account to see all 38 claims and to verify the 51 references still open.
- It may state two separate claims as one. 18
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated leptin and cholesterol levels are characteristic of obesity, and therefore these results further demonstrate the extent of the obese phenotype observed in Abi3–/– mice (Klop et al., 2013; Obradovic et al., 2021).”
From Deletion of the Alzheimer’s disease risk gene Abi3 locus results in obesity and systemic metabolic disruption in mice (2022) · cites this paper as Klop et al., 2013
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It is common for individuals afflicted with obesity to exhibit changes in the makeup of their circulating plasma fats, a condition known as dyslipidemia. This typically includes elevated levels of apolipoprotein B (apoB), diminished levels of high-density lipoprotein, and alterations in low-density lipoprotein’s particle composition (LDL).”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [51]
In the citing paper
“Obesity has a clear correlation with the incidence of cardiovascular disorders including hypertension, coronary artery disease, heart failure and sudden death”
In the citing paper
“many patients with insulin resistance, the main etiology of T2DM, tend to have high triglyceride and low HDL levels [53,54,55]”
In the citing paper
“Chronically elevated serum cholesterol, particularly LDL, contribute to the degenerative accumulation of plaques in the arteries, which can lead to progressive narrowing or blocking of blood vessels (Klop et al., 2013).”
From Population genomics reveal recent speciation and rapid evolutionary adaptation in polar bears (2014) · cites this paper as Klop et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 3. Obesity Induced Changes in Lipoprotein Metabolism and Atherogenic Effects
“the increased TG content within the LDL is hydrolyzed by hepatic lipase, which leads to the formation of small, dense LDL particles.”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 3. Obesity Induced Changes in Lipoprotein Metabolism and Atherogenic Effects
“Hypertriglyceridemia further induces an increased exchange of cholesterolesters (CE) and TG between VLDL and HDL and low density lipoproteins (LDL) by cholesterylester-transfer-protein (CETP). This leads to decreased HDL-C concentrations and a reduction in TG content in LDL.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 2. Overview of Lipoprotein Metabolism
“Within the circulation, the HDL particles also become enriched with cholesterol-esters by the action of cholesterylester-transfer-protein (CETP) and phospholipid transfer protein (PLTP).”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 2. Overview of Lipoprotein Metabolism
“In this process HDL acquires TG from TG-rich lipoproteins in exchange for cholesterol-esters as a direct consequence of the CETP action [11].”
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“However, there is controversy about the effectiveness of fibrate therapy on top of statin therapy since the ACCORD trial was unable to confirm a beneficial effect on cardiovascular endpoints by fenofibrate combined with statins in diabetic patients [156].”
BackgroundMechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“All these mechanisms have been related to the higher incidence of cardiovascular disease seen in obesity [82].”
BackgroundWaist circumference as a measure for indicating need for weight management
Lean, M. E. J., Han, T. S., & Morrison, C. E. (1995) · BMJ · doi:10.1136/bmj.311.6998.158 · Cited by 1,869 · cited 1×
“It has been shown that diurnal triglyceridemia in obese subjects correlates better to waist circumference than to body mass index [78,80], which is in agreement with the hypothesis that the distribution of adipose tissue modulates postprandial lipemia [81].”
ResultNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577 · cited 3×
“Cholesterol is taken up by the enterocytes via the specific cholesterol transporter Niemann-Pick C1 Like 1 protein (NPC1L1) [9,10].”
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Goldstein, J. L., & Brown, M. S. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179564 · Cited by 1,344 · cited 1×
“In contrast, LDL is primarily taken up by the liver via the LDL receptor [31,32].”
BackgroundRelation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Fatty acids, obesity, and insulin resistance: Time for a reevaluation
Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011) · Diabetes · doi:10.2337/db11-0425 · Cited by 896 · cited 2×
“insulin resistance as seen in obesity [17].”
Background
Cited by
Jung, U., & Choi, M.-S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,880
“hydrolyzed by hepatic lipase (HL) [173], leading to the formation of small, dense LDL particles that are associated with a higher risk of cardiovascular disease [174].”
BackgroundSamson, S. L., & Garber, A. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.009 · Cited by 746
Vekic, J., Zeljkovic, A., Stefanovic, A., Jelic-Ivanovic, Z., & Spasojevic-Kalimanovska, V. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.005 · Cited by 612
Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut
Joyce, S. A., MacSharry, J., Casey, P. G., Kinsella, M., Murphy, E. F., Shanahan, F., Hill, C., & Gahan, C. G. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323599111 · Cited by 604
“Reductions of this magnitude are likely to be physiologically relevant for the mammalian host (20).”
BackgroundEffects of Exercise to Improve Cardiovascular Health
Pinckard, K., Baskin, K. K., & Stanford, K. I. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00069 · Cited by 446
“In an obese state, circulating levels of triglycerides and LDL cholesterol are increased (63), causing small plaques to form under endothelial cells of the innermost surface of artery walls (34, 62, 64).”
BackgroundPopulation genomics reveal recent speciation and rapid evolutionary adaptation in polar bears
Liu, S., Lorenzen, E. D., Fumagalli, M., Li, B., Harris, K., Xiong, Z., Zhou, L., Korneliussen, T. S., Somel, M., Babbitt, C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.03.054 · Cited by 411
“Chronically elevated serum cholesterol, particularly LDL, contribute to the degenerative accumulation of plaques in the arteries, which can lead to progressive narrowing or blocking of blood vessels (Klop et al., 2013).”
BackgroundJayedi, A., Soltani, S., Zargar, M. S., Khan, T. A., & Shab-Bidar, S. (2020) · BMJ · doi:10.1136/bmj.m3324 · Cited by 396
Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues
Dilworth, L., Facey, A., & Omoruyi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147644 · Cited by 382
“While research associates adipokines, such as resistin and retinol-binding protein 4 with decreased insulin sensitivity, leptin and adiponectin are shown to have the opposite effect [84].”
BackgroundDyslipidemia and cardiovascular disease risk among the MASHAD study population
Hedayatnia, M., Asadi, Z., Zare-Feyzabadi, R., Yaghooti-Khorasani, M., Ghazizadeh, H., Ghaffarian-Zirak, R., Nosrati-Tirkani, A., Mohammadi-Bajgiran, M., Rohban, M., Sadabadi, F., et al. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01204-y · Cited by 367
Thijssen, E., van Caam, A., & van der Kraan, P. M. (2015) · Rheumatology · doi:10.1093/rheumatology/keu464 · Cited by 362
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“51 Upon direct infusion of carbohydrates or fats into the ileum, healthy human bodies witness a swift rise in GLP-1 plasma concentrations.”
BackgroundSirt3 Impairment and SOD2 Hyperacetylation in Vascular Oxidative Stress and Hypertension
Dikalova, A. E., Itani, H. A., Nazarewicz, R. R., McMaster, W. G., Flynn, C. R., Uzhachenko, R., Fessel, J. P., Gamboa, J. L., Harrison, D. G., & Dikalov, S. I. (2017) · Circulation Research · doi:10.1161/circresaha.117.310933 · Cited by 315
Dynamic lipidome alterations associated with human health, disease and ageing
Hornburg, D., Wu, S., Moqri, M., Zhou, X., Contrepois, K., Bararpour, N., Traber, G. M., Su, B., Metwally, A. A., Avina, M., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00880-1 · Cited by 260
Gusti, A. M. T., Qusti, S. Y., Alshammari, E. M., Toraih, E. A., & Fawzy, M. S. (2021) · Antioxidants · doi:10.3390/antiox10040595 · Cited by 235
“Several population surveys have shown that the obesity prevalence increases progressively from 20 to 60 years of age [54], and significant associations were reported between obesity and hyperglycemia [55], dyslipidemia [56], hyperinsulinemia [57], and hypertension [58].”
BackgroundObesity and cardiovascular health
Welsh, A., Hammad, M., Piña, I. L., & Kulinski, J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae025 · Cited by 239
“23 These abnormalities are driven by the combination of the greater delivery of free fatty acids and triglycerides to the liver from excess adipose tissue, insulin resistance, adipocyte dysfunction with reduced adiponectin and increased production of pro-inflammatory cytokines.”
BackgroundFontana, R., & Torre, S. (2016) · Nutrients · doi:10.3390/nu8020087 · Cited by 218
“Dyslipidemia is often observed in obese patients, with increased plasmatic triglycerides and free fatty acids, decreased HDL‐C (high‐density lipoprotein cholesterol) and slightly increased in LDL‐C (low‐density lipoprotein cholesterol) [63].”
BackgroundThe role of oxidative stress in the development of obesity and obesity-related metabolic disorders
Čolak, E., & Pap, D. (2021) · Journal of Medical Biochemistry · doi:10.5937/jomb0-24652 · Cited by 220
“These triglycerides are further, hydrolyzed by the action of hepatic lipase (HL), which leads to formation of small, dense LDL particles (59).”
BackgroundPonnulakshmi, R., Shyamaladevi, B., Vijayalakshmi, P., & Selvaraj, J. (2019) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2018.1545815 · Cited by 221
“A significant decrease in the levels of HDL may be due to a cholesteryl ester transfer protein-mediated exchange of triglycerides for cholesterol esters between triglyceride-rich lipoproteins (VLDL) and cholesterol-esters rich lipoproteins (LDL, HDL) (Klop et al. 2013). b-sitosterol significantly increased the levels…”
BackgroundInfluentialChoi, Y. J., Jeon, S.-M., & Shin, S. (2020) · Nutrients · doi:10.3390/nu12072005 · Cited by 193
“Obesity has a clear correlation with the incidence of cardiovascular disorders including hypertension, coronary artery disease, heart failure and sudden death, and many patients with insulin resistance, the main etiology of T2DM, tend to have high triglyceride and low HDL levels [53–55].”
BackgroundSeaweeds as Preventive Agents for Cardiovascular Diseases: From Nutrients to Functional Foods
Cardoso, S., Pereira, O., Seca, A., Pinto, D., & Silva, A. (2015) · Marine Drugs · doi:10.3390/md13116838 · Cited by 205
“Still, the recent growing understanding of multiple biological pathways underlying CVDs, including those of inflammation and oxidative stress [4,5], allowed the identification of additional biomarkers that can be useful for a more authentic and reliable estimation of cardiovascular risk, as well as to monitor the effi…”
BackgroundRegulation of lipoprotein lipase by Angptl4
Dijk, W., & Kersten, S. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.005 · Cited by 198
Eating behavior and eating disorders in adults before bariatric surgery
Mitchell, J. E., King, W. C., Courcoulas, A., Dakin, G., Elder, K., Engel, S., Flum, D., Kalarchian, M., Khandelwal, S., Pender, J., et al. (2015) · International Journal of Eating Disorders · doi:10.1002/eat.22275 · Cited by 199
Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function
Stadler, J. T., & Marsche, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238985 · Cited by 200
Effects of Mulberry Fruit (Morus alba L.) Consumption on Health Outcomes: A Mini-Review
Zhang, H., Ma, Z. F., Luo, X., & Li, X. (2018) · Antioxidants · doi:10.3390/antiox7050069 · Cited by 196
Singh, R., Rathore, S. S., Khan, H., Karale, S., Chawla, Y., Iqbal, K., Bhurwal, A., Tekin, A., Jain, N., Mehra, I., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.780872 · Cited by 193
Flavonoids as Antiobesity Agents: A Review
Rufino, A. T., Costa, V. M., Carvalho, F., & Fernandes, E. (2021) · Medicinal Research Reviews · doi:10.1002/med.21740 · Cited by 174
“Those lipoproteins are taken up by hepatocytes via, among others, the intervention of LDL receptors (LDLR).(34) Improving the LDLR capacity by increasing their expression will result in reduced cholesterol LDL levels, as well as enhanced uptake into the liver(34) (see Figure 1).”
BackgroundInfluentialRegulation of aldosterone synthesis and secretion.
Bollag, W. B. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130037 · Cited by 180
“cally have increases in lipoprotein levels, or dyslipidemia, and an elevated risk of hypertension and cardiovascular disease [reviewed in (161)].”
Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline
Ehtewish, H., Arredouani, A., & El-Agnaf, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116144 · Cited by 175
“Dyslipidemia refers to unhealthy high levels of triglycerides and/or low-density lipoprotein (LDL) and low levels of high-density lipoprotein (HDL) [64].”
BackgroundBarber, T. M., Kyrou, I., Randeva, H. S., & Weickert, M. O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020546 · Cited by 169
“Dyslipidaemia: IR results in enhanced hepatic flux of fatty acids originating from the diet and resistance to the antilipolytic effects of insulin within adipose tissue [31].”
BackgroundProtective Effects of (E)-β-Caryophyllene (BCP) in Chronic Inflammation
Scandiffio, R., Geddo, F., Cottone, E., Querio, G., Antoniotti, S., Gallo, M. P., Maffei, M. E., & Bovolin, P. (2020) · Nutrients · doi:10.3390/nu12113273 · Cited by 177
Lakkis, J. I., & Weir, M. R. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.005 · Cited by 177
Let food be your medicine: nutraceutical properties of lycopene
Grabowska, M., Wawrzyniak, D., Rolle, K., Chomczyński, P., Oziewicz, S., Jurga, S., & Barciszewski, J. (2019) · Food & Function · doi:10.1039/c9fo00580c · Cited by 172
Guillemot-Legris, O., Masquelier, J., Everard, A., Cani, P. D., Alhouayek, M., & Muccioli, G. G. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0666-8 · Cited by 168
“Indeed, HFD feeding will lead to an increase in the intake of saturated fatty acids [28] and to the disruption of cholesterol homeostasis (an increase in LDL to HDL cholesterol ratio) [29, 30], both associated with deleterious effects.”
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Bays, H. E., Kirkpatrick, C. F., Maki, K. C., Toth, P. P., Morgan, R. T., Tondt, J., Christensen, S. M., Dixon, D. L., & Jacobson, T. A. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.04.001 · Cited by 166
Wang, Q., Yuan, J., Yu, Z., Lin, L., Jiang, Y., Cao, Z., Zhuang, P., Whalen, M. J., Song, B., Wang, X.-J., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0663-7 · Cited by 156
“functions are typical features of the metabolic syndromes and may be associated with a pro-inflammatory gradient, which in part may originate in the adipose tissue itself and directly affect the endothelium and brain functions [59].”
Metabolic Profile and Long-Term Risk of Depression, Anxiety, and Stress-Related Disorders
Chourpiliadis, C., Zeng, Y., Lovik, A., Wei, D., Valdimarsdóttir, U., Song, H., Hammar, N., & Fang, F. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.4525 · Cited by 164
Normal-weight obesity syndrome: diagnosis, prevalence, and clinical implications
Franco, L. P., Morais, C. C., & Cominetti, C. (2016) · Nutrition Reviews · doi:10.1093/nutrit/nuw019 · Cited by 156
Obesity: A Review of Pathophysiology and Classification
Busebee, B., Ghusn, W., Cifuentes, L., & Acosta, A. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.05.026 · Cited by 159
Alterations of Plasma Lysophosphatidylcholine Species in Obesity and Weight Loss
Heimerl, S., Fischer, M., Baessler, A., Liebisch, G., Sigruener, A., Wallner, S., & Schmitz, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111348 · Cited by 152
Diet-Derived Antioxidants and Their Role in Inflammation, Obesity and Gut Microbiota Modulation
Deledda, A., Annunziata, G., Tenore, G. C., Palmas, V., Manzin, A., & Velluzzi, F. (2021) · Antioxidants · doi:10.3390/antiox10050708 · Cited by 183
“Among the various metabolic disorders, obesity is undoubtedly the main disorder strongly related to a chronic low-grade inflammation [81,82].”
BackgroundDeng, Y., Chen, H., Huang, Y., Zhang, Y., Ren, H., Fang, M., Wang, Q., Chen, W., Hale, R. C., Galloway, T. S., et al. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.1c07933 · Cited by 157
Zhang, H., Xu, Z., Zhao, H. W., Wang, X., Pang, J., Li, Q., Yang, Y., & Ling, W. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101474 · Cited by 157
Impact of intermittent fasting on the lipid profile: Assessment associated with diet and weight loss
Santos, H. O., & Macedo, R. C. O. (2018) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2018.01.002 · Cited by 172
Blodgett, J. M., Ahmadi, M. N., Atkin, A. J., CHASTIN, S. F. M., Chan, H., Suorsa, K., Bakker, E. A., Hettiarcachchi, P., Johansson, P. J., Sherar, L. B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad717 · Cited by 171
“This may have limited real-world plausibility compared with the potential impacts of displacing an additional ∼ 5 min in any other behaviour into MVPA.”
The Role of Lipids in the Regulation of Immune Responses
Garcia, C., Andersen, C. J., & Blesso, C. N. (2023) · Nutrients · doi:10.3390/nu15183899 · Cited by 161
Roles of G protein-coupled estrogen receptor GPER in metabolic regulation
Sharma, G., Mauvais-Jarvis, F., & Prossnitz, E. R. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.02.012 · Cited by 131
Alkhalidy, H., Moore, W., Zhang, Y., McMillan, R. P., Wang, A., Ali, M. M., Suh, K., Wei, Z. C., Cheng, Z., Jia, Z., et al. (2015) · Journal of Diabetes Research · doi:10.1155/2015/532984 · Cited by 151
RetractedANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during sustained cold exposure
Dijk, W., Heine, M., Vergnes, L., Boon, M. R., Schaart, G., Hesselink, M. K., Reue, K., van Marken Lichtenbelt, W. D., Olivecrona, G., Rensen, P. C., et al. (2015) · eLife · doi:10.7554/elife.08428 · Cited by 114
“…underlying fuel re-distribution may pave the way for new strategies to combat metabolic diseases, such as cardiovascular disease and diabetes type 2, in which a mismatch in regulation of lipid uptake and usage by tissues is an important feature (Klop et al., 2013; Young and Zechner, 2013).”
BackgroundTargeting metabolic disorders by natural products
Tabatabaei‐Malazy, O., Larijani, B. A., & Abdollahi, M. R. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0184-8 · Cited by 153
“TZDs have no or minimal effects on lipid profile in obesity [104, 105].”
BackgroundDyslipidemia and Kidney Stone Risk
Torricelli, F. C. M., De, S. K., Gebreselassie, S. K., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.09.022 · Cited by 134
Phytosterols: Nutritional Health Players in the Management of Obesity and Its Related Disorders
Vezza, T., Canet, F., Marañón, A., Bañuls, C., Rocha, M., & Víctor, V. M. (2020) · Antioxidants · doi:10.3390/antiox9121266 · Cited by 147
“It consists of an increased low-density lipoprotein (LDL)/very-low-density lipoproteins (VLDL)/triglycerides (TG), and decreased level of high-density lipoprotein (HDL) [110,111].”
BackgroundInfluentialCano-Sancho, G., Salmon, A. G., & La Merrill, M. A. (2017) · Environmental Health Perspectives · doi:10.1289/ehp527 · Cited by 131
“We retained 15 in vivo studies reporting associations between DDTs and abnormal lipids (Figure 4C,D), which is one of the main metabolic comorbidities associated with excessive body fat (Bays et al. 2013; Klop et al. 2013).”
Valckx, S., Arias‐Álvarez, M., Pauw, I. D., Fievez, V., Vlaeminck, B., Fransén, E., Bols, P. E. J., & Leroy, J. (2014) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-12-13 · Cited by 128
“A potential reason for this could be that in a first coping mechanism excess FAs, present in overweight individuals, are stored in lipid droplets [45].”
BackgroundObesity and cardiovascular risk
Kotsis, V., Jordan, J., Micić, D., Finer, N., Leitner, D. R., Toplak, H., Tokgözoğlu, L. S., Athyros, V. G., Elisaf, M., Filippatos, T. D., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001730 · Cited by 162
Targeting Inflammation by Flavonoids: Novel Therapeutic Strategy for Metabolic Disorders
Farzaei, M. H., Singh, A. K., Kumar, R., Croley, C. R., Pandey, A. K., Coy-Barrera, E., Kumar Patra, J., Das, G., Kerry, R. G., Annunziata, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194957 · Cited by 129
A critical review on anti-diabetic and anti-obesity effects of dietary resistant starch
Meenu, M., & Xu, B. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1481360 · Cited by 138
Siam, N. H., Snigdha, N. N., Tabasumma, N., & Parvin, I. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2512436 · Cited by 214
“Thus, it is evident that diabetic dyslipidemia is a very common event [78].”
Metabolic signals and innate immune activation in obesity and exercise
Ringseis, R., Eder, K., Mooren, F. C., & Krüger, K. (2026) · PubMed · doi:10.22029/eir.2015.1696 · Cited by 123
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 205
Theodorakis, N., & Nikolaou, M. (2025) · Biomolecules · doi:10.3390/biom15020213 · Cited by 175
“Meta-inflammation, dysregulated adipokine profiles, and insulin resistance further disrupt lipoprotein metabolism, compounding the dyslipidemic profile associated with obesity [14].”
Pathophysiological landscape of osteoarthritis
Kulkarni, P., Märtson, A., Vidya, R., Chitnavis, S., & Harsulkar, A. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.04.002 · Cited by 133
Weinstock, A., Brown, E. J., Garabedian, M. L., Pena, S., Sharma, M., Lafaille, J., Moore, K. J., & Fisher, E. A. (2019) · Immunometabolism · doi:10.20900/immunometab20190008 · Cited by 108
“Obese individuals have increased cardiovascular risk, and for the majority of them, this is the context of concurrent hyperlipidemia [33].”
BackgroundExercise as a Polypill for Chronic Diseases
Pareja-Galeano, H., Garatachea, N., & Lucía, A. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.07.019 · Cited by 128
Polydextrose: Physiological Function, and Effects on Health
do Carmo, M. M. R., Walker, J. C. L., Novello, D., Caselato, V. M., Sgarbieri, V. C., Ouwehand, A. C., Andreollo, N. A., Hiane, P. A., & dos Santos, E. F. (2016) · Nutrients · doi:10.3390/nu8090553 · Cited by 131
“Insulin is an important regulator of lipid metabolism, and therefore, insulin resistance in the peripheral tissues is a link between metabolic syndrome and dyslipidemia [51].”
BackgroundTargeting white, brown and perivascular adipose tissue in atherosclerosis development
van Dam, A. D., Boon, M. R., Berbée, J. F. P., Rensen, P. C. N., & van Harmelen, V. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.051 · Cited by 113
“Obesity is associated with hyperlipidaemia (Klop et al., 2013; Nordestgaard, 2016) and systemic inflammation (Hotamisligil, 2006; Shoelson et al., 2006), both of which are risk factors for atherosclerosis.”
BackgroundGuo, F., Gong, Z., Fernando, T., Zhang, L., Zhu, X., & Shi, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892125 · Cited by 126
“Increased influx of FFA to the liver, leading to hepatic accumulationofTG(40).”
BackgroundRegulation of Osteoclast Differentiation and Activity by Lipid Metabolism
Kim, H., Oh, B., & Park‐Min, K. (2021) · Cells · doi:10.3390/cells10010089 · Cited by 124
Santos, H. O., Earnest, C. P., Tinsley, G. M., Izidoro, L. F. M., & Macedo, R. C. O. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.009 · Cited by 114
Allicin Improves Metabolism in High-Fat Diet-Induced Obese Mice by Modulating the Gut Microbiota
Shi, X., Zhou, X., Chu, X., Wang, J., Xie, B., Ge, J., Guo, Y., Li, X., & Yang, G. (2019) · Nutrients · doi:10.3390/nu11122909 · Cited by 114
“Studies have found that obesity is often accompanied by high serum cholesterol (TC) and TG [18], high TG and low HDL-C associated with insulin resistance, and several metabolic diseases [19].”
BackgroundGestational dyslipidaemia and adverse birthweight outcomes: a systematic review and meta‐analysis
Wang, J., Moore, D., Subramanian, A., Cheng, K. K., Toulis, K. A., Qiu, X., Saravanan, P., Price, M. J., & Nirantharakumar, K. (2018) · Obesity Reviews · doi:10.1111/obr.12693 · Cited by 112
Management of eating disorders for people with higher weight: clinical practice guideline
Ralph, A. F., Brennan, L., Byrne, S., Caldwell, B., Farmer, J., Hart, L. M., Heruc, G. A., Maguire, S., Piya, M. K., Quin, J., et al. (2022) · Journal of Eating Disorders · doi:10.1186/s40337-022-00622-w · Cited by 107
Bais, S., Singh, G. S., & Sharma, R. (2014) · Advances in Biology · doi:10.1155/2014/162914 · Cited by 157
“Various parameters like cholesterol (TC), high density lipoproteins (HDL-C), triglycerides (TG), lowdensity lipoproteins (LDL-C), very low density lipoproteins (VLDLC), atherogenic index, percentage protection, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyrubic transaminase (SGPT), and total biliru…”
BackgroundInfluentialThe metabolic characteristics and changes of chondrocytes in vivo and in vitro in osteoarthritis
Adam, M. S., Zhuang, H., Ren, X., Zhang, Y., & Zhou, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1393550 · Cited by 127
“Disrupted lipid metabolism is linked to obesity (139).”
BackgroundInfluentialCigarette Smoking and Adipose Tissue: The Emerging Role in Progression of Atherosclerosis
Wang, Z., Wang, D., & Wang, Y. (2017) · Mediators of Inflammation · doi:10.1155/2017/3102737 · Cited by 101
“Blood lipid abnormalities caused by excess adipose tissue are classical features of metabolic syndrome, such as the presence of small dense LDL particles, which in part induce the proinflammatory place within the vascular wall [30].”
BackgroundTherapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 108
Pretorius, E., Bester, J., Vermeulen, N., Alummoottil, S., Soma, P., Buys, A. V., & Kell, D. B. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0192-5 · Cited by 95
“Type II diabetes is associated with three main glycaemic disorders: chronic hyperglycaemia; glycaemic variability; and iatrogenic hypoglycaemia [7], and also (frequently) comorbidities including dyslipidemia (high cholesterol levels) [8-11] and hypertension [12,13].”
BackgroundAnti-Obesity Effects of Dietary Calcium: The Evidence and Possible Mechanisms
Zhang, F., Ye, J., Zhu, X., Wang, L., Gao, P., Shu, G., Jiang, Q., & Wang, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123072 · Cited by 108
“It is now well established that obesity is able to progressively lead to and/or exacerbate a wide range of comorbidities [7–9], including insulin resistance and type 2 diabetes mellitus (T2DM) [10,11], dyslipidemia [12,13], hypertension [14,15], cardiovascular disease [16,17], nonalcoholic fatty liver disease [18,19],…”
BackgroundHDL and glucose metabolism: current evidence and therapeutic potential
Siebel, A. L., Heywood, S. E., & Kingwell, B. A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00258 · Cited by 104
“ApoA-I has been previously found in the CSF at relatively high levels (0.07–4 µg/mL or 0.1–0.5% plasma levels), (Koch et al., 2001) which is encouraging given the in vitro efficacy of ApoA-I at similar concentrations.”
InfluentialEo, H., Jeon, Y., Lee, M., & Lim, Y. (2014) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf502830b · Cited by 103
Al-Ghamdi, S. H., Shubair, M. M., Aldiab, A., Alzahrani, J. M., Aldossari, K. K., Househ, M. S., Nooruddin, S., Razzak, H. A., & El‐Metwally, A. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0778-5 · Cited by 111
“It is a modifiable and preventable risk factor for insulin resistance leading to impaired glucose tolerance [9], metabolic syndrome [18] and dyslipidemia [19].”
BackgroundResultInfluentialDNA methylation and lipid metabolism: an EWAS of 226 metabolic measures
Gomez-Alonso, M. D. C., Kretschmer, A., Wilson, R., Pfeiffer, L., Karhunen, V., Seppälä, I., Zhang, W., Mittelstraß, K., Wahl, S., Matías‐García, P. R., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-020-00957-8 · Cited by 93
Hellmuth, C., Uhl, O., Standl, M., Demmelmair, H., Heinrich, J., Koletzko, B. V., & Thiering, E. (2017) · Obesity Facts · doi:10.1159/000453001 · Cited by 83
Prevalence of Dyslipidemia and Associated Factors in Obese Children and Adolescents
Elmaoğulları, S., Tepe, D., Uçaktürk, S. A., Kara, F. K., & Demirel, F. (2015) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.1867 · Cited by 114
Ellulu, M. S. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0314-7 · Cited by 104
“…metabolic syndrome and dyslipidemia, observed in the development of insulin resistance in peripheral tissues leading to an enhanced hepatic flux of fatty acids from dietary sources, intravascular lipolysis and from adipose tissue resistant to the antilipolytic effects of insulin (Klop et al. 2013).”
BackgroundMichos, E. D., Lopez‐Jimenez, F., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 90
Omics Biomarkers in Obesity: Novel Etiological Insights and Targets for Precision Prevention
Aleksandrova, K., Rodrigues, C. E., Floegel, A., & Ahrens, W. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00393-y · Cited by 106
New Insights on Lipedema: The Enigmatic Disease of the Peripheral Fat
Bauer, A.-T., von Lukowicz, D., Lossagk, K., Aitzetmüller, M. M., Moog, P., Cerny, M., Erne, H. C., Schmauß, D., Duscher, D., & Machens, H. (2019) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000006280 · Cited by 107
G-Protein-Coupled Estrogen Receptor (GPER) and Sex-Specific Metabolic Homeostasis
Sharma, G., & Prossnitz, E. R. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-70178-3_20 · Cited by 88
“Obesity leads to altered secretory profiles of adipose-specific hormones and cytokines, increased levels of circulating glucose and lipids, and systemic inflammation, resulting in ectopic lipid deposition in peripheral metabolic tissues, such as the pancreas, liver, and skeletal muscle (Shulman 2014; Klop et al. 2013;…”
BackgroundTakić, M. M., Pokimica, B., Petrović-Oggiano, G., & Popović, T. (2022) · Molecules · doi:10.3390/molecules27144471 · Cited by 104
“According to the available literature data of numerous observational studies, the long-chain polyunsaturated fatty acid (LC-PUFA) status in circulation and tissues could be altered in overweight and obesity [5,12,15,22].”
BackgroundTrends in Lipids Level and Dyslipidemia among Chinese Adults, 2002-2015.
Song, P. K., Man, Q. Q., Li, H., Pang, S. J., Jia, S., Li, Y. Q., He, L., Zhao, W. H., & Zhang, J. (2019) · PubMed · doi:10.3967/bes2019.074 · Cited by 105
Hyppönen, E., & Boucher, B. J. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy034 · Cited by 97
Male obesity and subfertility, is it really about increased adiposity?
McPherson, N. O., & Lane, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.148076 · Cited by 104
Wan, Y., Xia, J., Xu, J., Chen, L., Yang, Y., Wu, J., Tang, F., Ao, H., & Peng, C. Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106002 · Cited by 93
The Role of the Gut Microbiota on the Beneficial Effects of Ketogenic Diets
Attaye, I., van Oppenraaij, S. L., Warmbrunn, M. V., & Nieuwdorp, M. (2021) · Nutrients · doi:10.3390/nu14010191 · Cited by 92
“A large clinical study and a review show that (abdominal) obesity and diabetes are common risk factors for dyslipidaemia [62,63].”
BackgroundHIIT is not superior to MICT in altering blood lipids: a systematic review and meta-analysis
Wood, G., Murrell, A., van der Touw, T., & Smart, N. (2019) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2019-000647 · Cited by 85
Vascular comorbidities in the onset and progression of multiple sclerosis
Tettey, P., Simpson, S., Taylor, B. V., & van der Mei, I. A. F. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.10.020 · Cited by 93
“If there were to be an independent effect of obesity, then the mechanism may be related to the lipid pathway, as obese people are known to have a more adverse lipid profile compared to those of normal weight [32,33], It is also possible that there is a shared pathway between vitamin D and lipids [34,35].”
Munteanu, C., & Schwartz, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158250 · Cited by 102
“Obesity is without a doubt the primary metabolic condition that is most closely linked to persistent low-grade inflammation [284,285].”
BackgroundSleep duration and abnormal serum lipids: the China Health and Nutrition Survey
Zhan, Y., Chen, R., & Yu, J. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.02.006 · Cited by 84
“Fat-rich food, low vitamin C, and obesity are risk factors for dyslipidemia [29,30].”
BackgroundKhutami, C., Sumiwi, S. A., Ikram, N. K. K., & Muchtaridi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042056 · Cited by 106
“Too many fat cells can cause liposomes (steatosis) in liver cells to expand and form large vacuoles associated with diseases, including non-alcoholic fatty liver disease (NAFLD), steatohepatitis and cirrhotic steatohepatitis [83].”
BackgroundInfluential
Metadata
- Authors
- Klop, B., Elte, J., & Cabezas, M.
- Affiliations
- Sint Franciscus Gasthuis (NL)
- Corresponding author
- Cabezas, Manuel
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2013-04-12
- Volume
- 5
- Issue
- 4
- Pages
- 1218-1240
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC3705344
- OpenAlex
- W1985399572
- Cited by
- 1,665
- References
- 169
- Citations by year
- 2026: 90 · 2025: 157 · 2024: 194 · 2023: 210 · 2022: 196 · 2021: 195 · 2020: 138 · 2019: 117 · 2018: 76 · 2017: 74 · 2016: 75 · 2015: 63 · 2014: 65 · 2013: 12
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- obesity, dyslipidemia, metabolic syndrome, insulin resistance, small dense LDL, postprandial hypertriglyceridemia, apolipoprotein B, hepatic lipogenesis, adipose tissue inflammation, endothelial dysfunction, cardiovascular risk, lipid metabolism, obesity treatment
- MeSH terms
- Hypolipidemic Agents, Humans, Insulin Resistance, Lipids, Obesity, Risk Factors, Biomarkers, Comorbidity, Treatment Outcome, Inflammation Mediators, Caloric Restriction, Risk Reduction Behavior, Dyslipidemias, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.